Reactive Arthritis Treatment Market to Hold a High Potential for Growth by 2027

0
11

Reactive arthritis is a form of joint inflammation, which affects the joints, heels, toes, lower back especially of the knees and ankles, and may also affect the skin, urinary tract and eyes. Reactive arthritis belongs to a group of orthopedic disorders which is commonly known as spondyloarthritis, which can cause inflammation throughout the body, especially in the spine. Reactive arthritis occurs when a bacteria (Chlamydia trachomatis with Shigella, Salmonella, Campylobacter, Yersinia, or Clostridium difficile)

enters the blood stream from urogenital tract and gastrointestinal tract. There are few instances where the bacteria in urogenital tract can enter through vagina or urethra and spread over the bladder while in the gastrointestinal tract. Reactive arthritis typically initiates within 2 to 4 week after infection. Reactive Arthritis can also create inflammation also can affect your eyes, skin, and urethra. As compared to men, women often have milder symptoms of reactive arthritis. Reactive arthritis usually tends to occur in men aged 40 and above.  Reactive arthritis is not a contagious disease.

Download sample copy of this report: 
https://www.futuremarketinsights.com/reports/sample/REP-GB-4982

Reactive Arthritis Treatment Market: Drivers and Restraints

Reactive arthritis treatment market is growing due to the increasing prevalence of reactive arthritis diseases across the globe. Moreover, few indication also shows that people who smokes often are at high risk of developing reactive arthritis. Additionally, increasing geriatric population, maintaining proper hygiene is expected to drive the global reactive arthritis treatment market. Increasing awareness about relation Reiter’s disease and arthritis is expected to create opportunity to the reactive arthritis treatment market. However, the stringent regulations by the government for drug approval, high cost associated with the treatment and diagnosis procedure and lack of experience are expected to act as a restraint to the reactive arthritis treatment market.

Reactive Arthritis Treatment Market: Segmentation

The global reactive arthritis treatment market is classified on the basis of drug type, route of administration and distribution channel.

Based on the drug type, the global reactive arthritis treatment market is segmented into the following:

Antibiotics

Corticosteroids

Nonsteroidal anti-inflammatory drugs (NSAIDs)

Disease modifying anti-rheumatic drugs (DMARDs)

Tumor necrosis factor (TNF) blockers

Immunosuppressant Drugs

Based on the route of administration, the global reactive arthritis treatment market is segmented into the following:

Oral

Topical/Transdermal

Parenteral

Based on the distribution channel, the global reactive arthritis treatment market is segmented into the following:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Reactive Arthritis TreatmentMarket: Overview

Based on the drug type, the market is segmented into corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), disease modifying anti-rheumatic drugs (DMARDs) and tropical steroids. Nonsteroidal anti-inflammatory drugs (NSAIDs) is the most widely used for relieve and pain of reactive arthritis. Based on the route of administration, the reactive arthritis treatment market is segmented into oral, topical/transdermal and parenteral. Based on the distribution channel, the reactive arthritis treatment market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Among the distribution channel, hospital pharmacies distribution channel segment is expected to contribute highest market share in global reactive arthritis treatment market.

Reactive Arthritis Treatment Market: Regional Overview

Region wise, the global reactive arthritis treatment market is classified North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific Ex. Japan, Japan, Middle East and Africa. North America is expected to lead the market due to better economic condition, better healthcare facilities and better government initiatives and more business investments for research and development. Europe market is expected to hold second largest market share followed by Latin America due to increasing awareness and increasing adoption of treatment for reactive arthritis.

Download table of contents with figures & tables: 
https://www.futuremarketinsights.com/askus/rep-gb-4982

Reactive Arthritis Treatment Market: Key Players

Some of the players in reactive arthritis treatment market includes F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Novartis AG, Amgen Inc., Velcura Therapeutics, Inc., Bayer AG, Geri-Care Pharmaceuticals, Merck Sharp & Dohme Corp, UCB S.A., Johnson & Johnson Services, Inc, Bristol-Myers Squibb Company, and AbbVie Inc., among others.

LEAVE A REPLY

Please enter your comment!
Please enter your name here